Precision Biosciences Inc

NASDAQ:DTIL  
1.54
-0.06 (-3.75%)
Products, Strategic Combinations

Precision Biosciences Announces In Vivo Gene Editing Collaboration With Novartis

Published: 06/21/2022 21:08 GMT
Precision Biosciences Inc (DTIL) - Precision Biosciences Announces in Vivo Gene Editing Collaboration With Novartis to Develop Potentially Curative Treatment for Disorders Including Sickle Cell Disease.
Precision Biosciences Inc - Precision to Receive $75 Million Upfront for a Single Target.
Precision Biosciences - Precision Eligible to Receive Up to an Additional $1.4 Billion in Milestones and Tiered Royalties on Sales of Licensed Products.
Precision Biosciences Inc - Extends Precision's Cash Runway Into Q2 2024.